214 related articles for article (PubMed ID: 956659)
1. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
Robertson J; Caldwell JR; Castle JR; Waldman RH
J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
[TBL] [Abstract][Full Text] [Related]
2. Activation of the alternative pathway of complement by human serum IgA.
Hiemstra PS; Gorter A; Stuurman ME; Van Es LA; Daha MR
Eur J Immunol; 1987 Mar; 17(3):321-6. PubMed ID: 3569402
[TBL] [Abstract][Full Text] [Related]
3. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
4. Complement system in human colostrum: presence of nine complement components and factors of alternative pathway in human colostrum.
Nakajima S; Baba AS; Tamura N
Int Arch Allergy Appl Immunol; 1977; 54(5):428-33. PubMed ID: 885627
[TBL] [Abstract][Full Text] [Related]
5. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
[TBL] [Abstract][Full Text] [Related]
6. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
7. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
Rits M; Hiemstra PS; Bazin H; Van Es LA; Vaerman JP; Daha MR
Eur J Immunol; 1988 Dec; 18(12):1873-80. PubMed ID: 3220102
[TBL] [Abstract][Full Text] [Related]
8. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
Arnaout MA; Davis AE; Rosen RS; Alper CA
J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of proteins in sputum from patients with chronic obstructive lung disease. II. Determination of albumin, transferrin, alpha1-acid glycoprotein, IgG, IgM, lysozyme and C3-complement factor.
Kotlar HK; Harbitz O; Jenssen AO; Smidsrød O
Eur J Respir Dis; 1980 Aug; 61(4):233-9. PubMed ID: 7202596
[TBL] [Abstract][Full Text] [Related]
10. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
[TBL] [Abstract][Full Text] [Related]
11. The concentrations of IgA and free secretory piece in the nasal secretions of patients with recurrent respiratory infections.
Stanley PJ; Cole PJ
Clin Exp Immunol; 1985 Jan; 59(1):197-202. PubMed ID: 3918818
[TBL] [Abstract][Full Text] [Related]
12. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
13. Activation of the alternative pathway of the complement system by radiographic contrast media.
Arroyave CM; Bhat KN; Crown R
J Immunol; 1976 Nov; 117(5 Pt.2):1866-9. PubMed ID: 993582
[TBL] [Abstract][Full Text] [Related]
14. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
15. Partial properdin deficiency.
Davis CA; Forristal J
J Lab Clin Med; 1980 Oct; 96(4):633-9. PubMed ID: 6903190
[TBL] [Abstract][Full Text] [Related]
16. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
[TBL] [Abstract][Full Text] [Related]
17. Differences between IgA and IgE as secretory proteins.
Nakajima S; Gillespie DN; Gleich GJ
Clin Exp Immunol; 1975 Aug; 21(2):306-17. PubMed ID: 1183074
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated enhancement of IgA-induced H2O2 release by human polymorphonuclear leucocytes.
Gorter A; Hiemstra PS; Leijh PC; van der Sluys ME; van den Barselaar MT; Van Es LA; Daha MR
Immunology; 1989 May; 67(1):120-5. PubMed ID: 2737694
[TBL] [Abstract][Full Text] [Related]
19. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
20. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
